Clinical Edge Journal Scan

Intestinal metaplasia before H. pylori eradication hints at post-eradication gastric cancer surveillance


 

Key clinical point: Patients with histological intestinal metaplasia (IM) before eradication of Helicobacter pylori infection, especially at the corpus lesser curvature, may be at an increased risk for gastric cancer after successful eradication.

Major finding: Patients who did vs did not develop gastric cancer had significantly higher histological IM scores at all biopsy sites (P < .05) and a higher proportion of operative link on gastric IM (OLGIM) III/IV stage (P < .01). The corpus lesser curvature had the highest area under the receiver operating characteristic curve value for IM score (0.82), which was similar to OLGIM score (0.82).

Study details: This single-center retrospective study included 247 patients who were diagnosed as positive for H. pylori and achieved infection eradication, of which 11 patients developed gastric cancer after eradication therapy.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Hara D et al. Histopathologically defined intestinal metaplasia in lesser curvature of corpus prior to Helicobacter pylori eradication is a risk factor for gastric cancer development. Helicobacter. 2022;27(6):e12934 (Oct 20). Doi: 10.1111/hel.12934

Recommended Reading

High risk for incident cardiovascular disease in patients with high-risk stage II-III CRC
MDedge Hematology and Oncology
CRC: Severe inflammatory response in early postoperative period increases risk for recurrence
MDedge Hematology and Oncology
Excellent prognostic ability of neutrophil-to-lymphocyte ratio in CRC liver metastasis
MDedge Hematology and Oncology
mCRC: Triplet+bevacizumab offers survival advantage even in patients with bone metastasis
MDedge Hematology and Oncology
Comparative analysis of total neoadjuvant therapy vs standard therapy in LARC
MDedge Hematology and Oncology
ctDNA detection following curative surgery for colorectal cancer predicts poor prognosis
MDedge Hematology and Oncology
Bemarituzumab shows promising efficacy in patients with FGFR2b-selected gastric cancer
MDedge Hematology and Oncology
Gastric ulcer increases the risk for gastric cancer
MDedge Hematology and Oncology
Preoperative D-dimer-to-albumin ratio: A biomarker for long-term prognosis in gastric cancer
MDedge Hematology and Oncology
Disease progression pattern linked with poor prognosis in advanced gastric cancer patients on nivolumab
MDedge Hematology and Oncology